©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jan 26, 2015; 7(1): 160-164
Published online Jan 26, 2015. doi: 10.4252/wjsc.v7.i1.160
Published online Jan 26, 2015. doi: 10.4252/wjsc.v7.i1.160
Stem cell therapy for retinal diseases
José Mauricio Garcia, Luisa Mendonça, Murilo Abud, Bruno Diniz, Department of Ophthalmology, Universidade Federal de Goiás, Goiânia 74001-970, Brazil
Rodrigo Brant, Caio Regatieri, Bruno Diniz, Department of Ophthalmology, Universidade Federal de São Paulo, São Paulo 04023-062, Brazil
Author contributions: All authors contributed to this paper.
Correspondence to: Bruno Diniz, MD, PhD, Department of Ophthalmology, Universidade Federal de Goiás, Al. Ricardo Paranhos, 799, Goiânia 74001-970, Brazil. dinizb@me.com
Telephone: +55-62-35211000
Received: July 29, 2014
Peer-review started: July 29, 2014
First decision: August 14, 2014
Revised: September 26, 2014
Accepted: October 14, 2014
Article in press: December 16, 2014
Published online: January 26, 2015
Peer-review started: July 29, 2014
First decision: August 14, 2014
Revised: September 26, 2014
Accepted: October 14, 2014
Article in press: December 16, 2014
Published online: January 26, 2015
Core Tip
Core tip: The stem cell (SC) retinal therapy has turned into an potentially useful way of treating blinding disorders, such as, Stargadt’s dystrophy, and geographic atrophy. The Food and Drug Administration’s approval for clinical trials using SC retinal therapy, and its good results, may appoint to future promising outcomes, providing an anatomical restoration of the retina, and a functional improval of visual function of several patients.